Last year, they successfully lobbied against the confirmation of Gary Skiba, a hunter, angler, bighorn sheep biologist, and 23-year veteran of Colorado Parks and Wildlife, because he supported wolf ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

AN outbreak of a lethal ‘eye-bleeding’ virus has been confirmed in Tanzania, the president has announced. It comes just a ...

Minister, Andrew Muir, has updated his Stormont Executive colleagues about the ongoing outbreak of Foot and Mouth Disease ...

Herder supercomputer coming in 2027 Hundreds of AMD APUs fired up on Thursday as Germany's High-Performance Computing Center ...

Copyright 2025 The Associated Press. All Rights Reserved. A sign that reads: “Caution, risk of epidemic!” is displayed on a ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

This designation is in addition to Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, all previously granted by the FDA for tividenofusp alfa in Hunter syndrome.

Hunter syndrome affects over 2,000 individuals, primarily males, in commercially accessible regions. With analysts maintaining a Strong Buy consensus and the company maintaining a healthy liquidity ...